Alnylam Just Lost $10 Billion and Is Blaming Its Own Launch

Let's get the ugly part out of the way first, because it's the whole story. Alnylam Pharmaceuticals cut its full-year 2026 guidance by roughly $200 million and the market reacted like someone stepped on a rake. The stock fell over 28% on the news. It's down roughly 45% over the trailing twelve months. American Century named it a detractor in its own quarterly letter — a rare and slightly humiliating thing to have happen to a company you own. The shares closed at $258 on September 9, a market cap near $34.5 billion.

Kessler Topaz Meltzer & Check, a plaintiff law firm, has already announced it's investigating the July 30 guidance cut for potential securities violations. Keep in mind that's attorney advertising, not a verdict. But the timing tells you exactly how the buy side read the tape.

Here's the part that keeps me up at night, though. This wasn't a disaster of the top line. Alnylam posted $1,172 million in global net product revenue in Q2 — 74% up year over year. The TTR franchise alone did $1,030 million, 89% growth, driven almost entirely by AMVUTTRA at $1,012 million. Adjusted EPS of $1.84 beat. By every traditional metric, this is a company winning.

So why did $10 billion evaporate?

Because the cut wasn't about what happened. It was about what's coming. Management framed the guidance reduction as the "initial phase of our launch in the evolving ATTR-CM market" and the "normalization of growth in second line volume." Translation: AMVUTTRA's foray into heart failure with ATTR (ATTR-CM) is ramping slower than the models assumed, and second-line demand is settling down from an initially elevated pace. That's not a broken product. That's a launch meeting reality. And the market, having run the stock up on a $8.8 billion revenue / $1.8 billion earnings 2029 story, suddenly had to price in a world where "slower" means "slower."

Now the interesting part.

While everyone was staring at the guidance cut, Alnylam quietly delivered one of the better Phase 3 data sets in the space. HELIOS-B, presented at Heart Failure 2026 in August, showed vutrisiran reducing all-cause mortality and recurrent cardiovascular events in ATTR-CM patients across a broad range of heart failure therapies. A pooled analysis of over 25,000 patient-years showed a consistent safety profile, including no clinically meaningful ocular effects from vitamin A lowering. That is the kind of data that expands an addressable market, not shrinks it. This is the same franchise that's the only product approved for the full spectrum of ATTR amyloidosis.

The market threw the baby out with the bathwater. Or at least threw the stock out with the guidance cut.

Here's my actual read: the bears are right about the near term and wrong about the decade. The payer pressure and margin compression are real — they're the single biggest cited risk, and they're not going away. AMVUTTRA will face competitors like acoramidis eating into the ATTR space, and adoption will be a marathon, not a sprint. The guidance cut was honest, and honesty after a euphoric run usually means more pain, not less.

But the thesis isn't broken. Alnylam's pipeline is genuinely wide: ALN-6400 in von Willebrand Disease and mivelsiran in Down syndrome-associated Alzheimer's both entered Phase 2, Phase 1 data from ALN-HTT02 in Huntington's is heading to EHDN, and zilebesiran keeps making the case for RNAi as a once-continuous blood pressure therapy. That's not one drug and a prayer. That's a platform.

So what's the setup? Technically, the stock is consolidating after the whipsaw — down 29% on the guidance cut, then recovering into a structural base somewhere in the $217 to $240 zone, with $250 to $300 as heavy resistance overhead. The 52-week low of $197.81 is the line in the sand if support fails. Momentum alone is unreliable here; this stock is a binary-event machine.

The one event that matters, and everything hinges on it: Q3 earnings, tentatively scheduled for October 29. That print either restores management's credibility on the TTR ramp or confirms the "normalization" story is worse than expected. The three dated calendar events floating around — a September 20 trial announcement and an November 10 trial results release — are unverified leads, so treat them as noise until Alnylam's own IR confirms them.

My take: this is a hold with a bias toward buying the structural support zone, not a chase. The valuation is stretched if growth disappoints again, but the pipeline gives it a floor the market is underpricing right now. Avoid trying to catch the knife on the downside or FOMO a breakout — wait for a clean, sustained break above $250 before calling it. Alnylam didn't break in this cycle. It just got told its launch would take longer than expected, and the bought-by-the-rumor crowd didn't like hearing it.